2 Top Biotech Stocks to Buy Right Now
It's been a rough year for the biotech industry, which as a whole has substantially lagged the broader market. Just look at the performance of the SPDR S&P Biotech ETF, an industry benchmark. What's more, some biotechs have been encountering their own company-specific issues.
Two worth a closer look today are Amgen (NASDAQ: AMGN) and Moderna (NASDAQ: MRNA) whose prospects really don't look as bad as their year-to-date performances suggest. At current levels, both Amgen and Moderna are worth investing in now. Let's find out why.
Source Fool.com
Amgen Inc. Stock
The stock is one of the favorites of our community with 42 Buy predictions and 4 Sell predictions.
On the other hand, the target price of 343 € is below the current price of 367.95 € for Amgen Inc., so the potential is actually -6.78%.



